Fortress Biotech reported a strong third quarter with significant revenue growth driven by its marketed dermatology products and strategic monetization events. The company achieved profitability and a substantial increase in cash reserves, underscoring the validation of its diversified business model and successful asset advancement.
Total net revenue increased 20.5% to $17.6 million for Q3 2025 compared to Q3 2024.
positiveFortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma, generating ~$28 million upfront for Fortress, with potential for additional CVR payments and royalties.
positiveConsolidated net income attributable to common stockholders was $3.7 million, or $0.13 per basic share and $0.11 per diluted share, a significant improvement from a net loss in the prior year.
positiveConsolidated cash and cash equivalents increased by $28.9 million year-to-date to $86.2 million as of September 30, 2025.
positiveJourney Medical's net product revenues were $17.0 million for Q3 2025, up from $14.6 million in Q3 2024.
positiveDotinurad is advancing in two Phase 3 clinical trials, supported by a $205 million Series A financing for Crystalys Therapeutics.
positiveConsolidated research and development expenses were $0.2 million for Q3 2025, a significant decrease from $9.4 million in Q3 2024, potentially indicating a shift in R&D focus or pipeline stage.
attentionWhile net income improved, consolidated selling, general and administrative costs were $17.4 million for Q3 2025, which is still a substantial expense relative to current revenue.
attentionThe FDA issued a Complete Response Letter (CRL) for the NDA for CUTX-101, citing cGMP deficiencies at the manufacturing facility, although Sentynl expects to resubmit the NDA shortly.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
The acquisition of two subsidiaries this year, Checkpoint Therapeutics and Baergic Bio, are strategic exits that represent validation of our approach.
The sale of Checkpoint generated approximately $28 million in upfront consideration, with the potential for additional contingent value right (CVR) payments and future royalty income.
Journey Medical Corporation continues to deliver strong operational execution, highlighted by the successful launch of Emrosi™ and accelerating commercial performance.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.